Transition, Actinide, Or Lanthanide Metal Containing Patents (Class 424/9.36)
-
Publication number: 20130052141Abstract: A hyperpolarized MR imaging medium and a method of 13C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarised [13C, 2H]lactate.Type: ApplicationFiled: May 2, 2011Publication date: February 28, 2013Applicant: GE HEALTHCARE LIMITEDInventors: Kevin Brindle, Mikko Iivari Kettunen, Brett W.C. Kennedy
-
Patent number: 8361438Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.Type: GrantFiled: January 8, 2009Date of Patent: January 29, 2013Assignee: Lantheus Medical Imaging, Inc.Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
-
Patent number: 8361437Abstract: Multimodal nanoparticles are nanoparticles containing contrast agents for PAT and one or more of luminescence imaging, x-ray imaging, and/or MRI. The multimodal nanoparticles can have a dielectric core comprising an oxide with a metal coating on the core. The particles can be metal speckled. The multimodal nanoparticles can be used for therapeutic purposes such as ablation of tumors or by neutron capture in addition to use as contrast agents for imaging.Type: GrantFiled: August 28, 2008Date of Patent: January 29, 2013Assignee: University of Florida Research Foundation, Inc.Inventors: Parvesh Sharma, Brij M. Moudgil, Glenn A. Walter, Stephen R. Grobmyer, Swadeshmukul Santra, Huabei Jiang, Scott Chang Brown, Edward W. Scott, Qizhi Zhang, Niclas Bengtsson
-
Patent number: 8323621Abstract: Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue.Type: GrantFiled: March 4, 2008Date of Patent: December 4, 2012Assignees: Vanderbilt University, Texas Tech University SystemInventors: Darryl J. Bornhop, H. Charles Manning, Timothy Goebel
-
Patent number: 8303937Abstract: A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of SP-DZ-L)i)j or SP-DX-Z-L)i)j, wherein, S is cyclosilane moiety with j silicon oxygen residual groups, and j is not less than 2; P is and l is not less than 1; D is a C3-30 dendritic moiety having n oxygen residue, and n is not less than 3; X is C3-30 moiety having bi-functional groups; Z is a C3-20 moiety having a plurality of functional group; and L is a metal cation.Type: GrantFiled: July 16, 2008Date of Patent: November 6, 2012Assignee: Industrial Technology Research InstituteInventors: Dhakshanamurthy Thirumalai, Chin-I Lin, Shian-Jy Wang
-
Patent number: 8299285Abstract: A metal complex of formula (III) wherein: M is a transition metal and A1, A2, X, X?, Y, L1?, R1? and R2? are as defined herein, is useful in medical imaging and therapy.Type: GrantFiled: July 5, 2006Date of Patent: October 30, 2012Assignee: Isis Innovation LimitedInventors: Jonathan Robin Dilworth, Josephine Mary Peach, Julia May Heslop, Paul Stephen Donnelly
-
Publication number: 20120269736Abstract: This invention relates to a composition comprising a micelle for use in biological applications, the micelle comprising: a substantially water-insoluble conjugated polymer which exhibits luminescence or fluorescence from about 300 nm to about 1500 nm of the electromagnetic spectrum: a biocompatible surfactant and/or lipid: and a MRI active agent.Type: ApplicationFiled: September 28, 2010Publication date: October 25, 2012Applicant: KING'S COLLEGE LONDONInventors: Mark Green, Philip Howes
-
Publication number: 20120189551Abstract: Novel, non-toxic cobalt-based contrast and imaging agents for use in enhanced medical imaging modalities and processes are described, as well the manufacture of markers containing such contrast agents is described, and uses for such imaging markers and contrast agents in a variety of therapeutic applications and devices.Type: ApplicationFiled: January 20, 2012Publication date: July 26, 2012Inventors: Steven J. Frank, Karen Martirosyan
-
Publication number: 20120087860Abstract: In another embodiment, a method for detecting and/or diagnosing a cancer in a subject is provided. The method may include administering an effective dose of a biotag to a subject, or alternatively, administering an effective dose of a targeted contrast to the subject, the targeted contrast comprising a contrast agent and a biotag as described herein for targeting a cancer biomarker. The method may further include exposing the subject to a diagnostic imaging technique; detecting a population of cells expressing the cancer biomarker; and quantifying the expression of the cancer biomarker in the population of cells, wherein an increased expression of the cancer biomarker indicates that the subject has cancer.Type: ApplicationFiled: May 24, 2011Publication date: April 12, 2012Inventors: Marek Malecki, Raf Malecki
-
Publication number: 20120070383Abstract: The present invention features compositions in which nano-carriers are synthesized with polymers that respond to lower pH and/or ROS by being degraded. The compositions may be utilized to selectively deliver payloads within patients by responding to lower pH and/or ROS at localities within the patient. The present invention also features methods of synthesizing nano-carriers that are degraded by lower pH and/or ROS.Type: ApplicationFiled: September 16, 2011Publication date: March 22, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Adah Almutairi, Jagadis Sankaranarayanan, Enas Mahmoud, Eric Schopf
-
Patent number: 8128908Abstract: The present invention relates to fluorescent, radio-opaque and magnetic quantum nanoparticles, useful as multifunctional contrast agents or probes for in vivo bioimaging, and methods of their use. The invention provides for multifaceted bioimaging (e.g., intra-arterial pre-operative brain mapping and broad based in vivo diagnostic imaging), including imaging of various cell types, such as stem cells.Type: GrantFiled: May 2, 2005Date of Patent: March 6, 2012Assignee: University of Florida Research Foundation, Inc.Inventors: Swadeshmukul Santra, Paul H. Holloway, Robert A. Mericle, Heesun Yang, Glenn A. Walter
-
Publication number: 20120052004Abstract: A contrast agent composition comprising at least one carbon nanotube and a metal catalyst. A method for obtaining a magnetic resonance image, the method comprising: administering to a subject a contrast agent composition, wherein a contrast agent composition comprises at least one carbon nanotube and a metal catalyst; and obtaining a magnetic resonance image of at least a portion of the subject in which the contrast agent is disposed.Type: ApplicationFiled: February 7, 2011Publication date: March 1, 2012Inventors: Lon J. Wilson, Jeyarama Subramanian Ananta Narayanan, Balaji Sitharaman, Keith Bennett Hartman
-
Publication number: 20120027690Abstract: The present document relates to a manufacturing method for pH-sensitive graft polymer micelles and a polymer micelle-type pharmaceutical composition containing the graft copolymer. The pH-sensitive graft copolymer micelles are usable as various markers and contrast agents for various molecular images for the diagnosis and treatment of diseases and a carrier for delivery of various medicines according to disease. The pH-sensitive graft copolymer forms micelles that can be used in target-oriented diagnosis and medicine release according to changes in the pH of a body. The polymer micelles are provided by inducing a graft copolymer of poly(?-amino ester) compounds which has a solubility in water depending on pH but is incapable of forming the micelles due to a self-assembly phenomenon, and hydrophilic poly(ethylene glycol) compounds.Type: ApplicationFiled: April 9, 2010Publication date: February 2, 2012Applicant: Research & Business Foundation Sungkyunkwan UniversityInventors: Doo Sung Lee, Min Sang Kim, Bong Sup Kim
-
Patent number: 8092783Abstract: Gadolinium+3 (Gd3+) containing (or incorporated) Prussian blue lattice contrast agents that can be used as an MRI contrast agent have unexpectedly improved r1 relaxivities of 1 or 2 magnitudes higher than the commercial Gd3+-chelates as well as exceedingly, non-toxic, low release of the Gd3+ ions into an aqueous environment at a pH of about 2 to about 7.5. The Prussian blue lattice containing Gd3+ ions therein can be used for clinical diagnosis intravenously to human beings for medical imaging. The particle sizes of the doped Prussian blue lattices are of a nanosize scale and are very stable against agglomeration.Type: GrantFiled: April 3, 2009Date of Patent: January 10, 2012Assignee: Kent State UniversityInventors: Songping D. Huang, Yongxiu Li, Mohammadreza Shokouhimehr
-
Patent number: 8092782Abstract: The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.Type: GrantFiled: September 10, 2008Date of Patent: January 10, 2012Assignee: The General Hospital CorporationInventors: David R. Elmaleh, Timothy M. Shoup, Alan J. Fischman
-
Publication number: 20120003160Abstract: Methods for performing macrophage-enhanced MRI, utilizing a macrophage imaging agent, in a single imaging session are provided. The macrophage imaging agent may be an ultrasmall superparamagnetic iron oxide particle. One embodiment includes administering a macrophage imaging agent to the subject during an administration session then allowing a passage of time sufficient for accumulation of the agent in macrophages of the subject. Subsequently, in a single imaging session, a macrophage-enhanced magnetic resonance image is acquired to target macrophages and a different magnetic resonance image is acquired to target physiological phenomenon other than macrophages. Additional embodiments provide methods wherein the acquisition of a different magnetic resonance image is achieved by vascular-enhanced MRI protocols or perfusion-enhanced MRI protocols, or combinations thereof. Further embodiments provide methods for utilizing acquired images in assessment of treatment of disease.Type: ApplicationFiled: August 3, 2011Publication date: January 5, 2012Applicant: AMAG PHARMACEUTICALS, INC.Inventors: Gerald L. Wolf, Jerome M. Lewis
-
Publication number: 20120004530Abstract: Quantitative assessment of magnetic agent tagged cells in a subject comprises: acquiring a series of T2 weighted images of the subject; acquiring a series of T2* weighted images of the subject; and generating a value indicative of quantitative assessment of magnetic agent tagged cells in the subject based on both the T2 weighted images of the subject and the T2* weighted images of the subject. The generating may be further based on predetermined relationships (26) between (i) R2 and intracellular magnetic agent concentration, (ii) R2* and intracellular magnetic agent concentration, (iii) R2 and extracellular magnetic agent concentration, and (iv) R2* and extracellular magnetic agent concentration. Said predetermined relationships may be generated based on R2 and R2* measurements of a plurality of calibration phantoms having different concentrations of substantially purely intracellular magnetic agent and having different concentrations of substantially purely extracellular magnetic agent.Type: ApplicationFiled: February 9, 2010Publication date: January 5, 2012Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Wei Liu, Julien Senegas, Stefanie Remmele
-
Publication number: 20110243858Abstract: A method of diagnostic imaging is disclosed comprising administering a medical formulation to a subject, the formulation comprising a contrast enhancement agent having structure I and salts thereof wherein R1 is independently at each occurrence a hydroxy group, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, and b is 0-4; R2-R7 are independently at each occurrence hydrogen, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, with the proviso that at least one of R1-R7 is a hydroxy group or a C1-C3 hydroxyalkyl group; and wherein Q is one or more charge balancing counterions; and one or more pharmaceutically acceptable carriers and excipients. The subject is subjected to a diagnostic imaging technique such as magnetic resonance imaging. The technique may be used in a variety of diagnostic imaging regimes, such as imaging of circulatory systems, genitourinary systems, hepatobiliary systems, central nervous systems, tumors, and abscesses among others.Type: ApplicationFiled: March 31, 2011Publication date: October 6, 2011Applicant: GENERAL ELECTRIC COMPANYInventors: Brian James Grimmond, Michael James Rishel, Rong Zhang, Jeannette Christine Roberts
-
Patent number: 8021646Abstract: The present application provides for compositions and methods of creating and applying contrast agents that find use in magnetic resonance imaging (MRI). In particular, contrast agents that comprise monodisperse, protein polymer backbones capable of chelating multiple paramagnetic ions resulting in high relaxivity for use in enhancing MRI signal intensity.Type: GrantFiled: December 7, 2007Date of Patent: September 20, 2011Assignee: Northwestern UniversityInventors: Lindsay K. Sulzer, Steven R. Bull, Annelise Emily Barron, Thomas J Meade
-
Patent number: 8017105Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: June 22, 2006Date of Patent: September 13, 2011Assignee: Lantheus Medical Imaging, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Patent number: 8012458Abstract: The invention is directed to a lanthamide chelate composition having a lanthamide, a charged amidate ligand, and a mono- or bidentate neutrally charged coordination compound, the composition being represented by structure I or structure II wherein Ln3+ designates lanthamide, R1 is alkyl, aryl, or heteroaryl; R2 is alkyl, aminoalkyl, aryl or heteroaryl; M is a neutrally charged monodentate coordination compound, M? is a neutrally charged bidentate coordination compound, a=1 or 2; and wherein M and M? comprise N, S, or O. It extends to the process of making the composition.Type: GrantFiled: June 8, 2007Date of Patent: September 6, 2011Assignee: E. I. du Pont de Nemours and CompanyInventor: Damien F. Reardon
-
Publication number: 20110206603Abstract: Timed-bioresorbable particulates, particularly microspheres or fibers, may be used as a vehicle for delivery of radioisotopes, such as Y-90 and Pd-103 for localized radiotherapy, or as an embolic device. These particulates may also be embedded in polymers, or dispersed in injectable gels or other injectable media for the treatment of various cancers. The benefit of bioresorption, the ability to control the ratio of radioisotopes in the particulate, especially the gamma and beta ratios such as In-111/Y-90 ratio in a particulate, and the benefit of non-conductive implants are disclosed.Type: ApplicationFiled: February 18, 2011Publication date: August 25, 2011Applicant: XL SCI-TECH, INC.Inventors: Yongren Benjamin PENG, Xingye Cherry Lei
-
Publication number: 20110200534Abstract: The present invention relates a T1-T2 dual-modal MRI (magnetic resonance imaging) contrast agent, comprising (a) a first layer consisting of T1 contrast material; (b) a second layer consisting of T2 contrast material; and (c) a separating layer which is present in a space between the first layer and the second layer, and inhibits a reciprocal interference between T1 contrast material and T2 contrast material, and a heat-generating composition and a drug delivery composition having the same. The T1-T2 dual-modal contrast agent of the present invention may generate both T1 and T2 signal and thus observe the signal complementarily, resulting in accurate diagnosis through reduction of misdiagnosis. Further, T1 and T2 MR imaging may be simultaneously obtained by simple operation within the same MR imaging device, enabling to remarkably reduce a diagnosis time and diagnosis cost.Type: ApplicationFiled: August 21, 2009Publication date: August 18, 2011Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UInventors: Jin Woo Cheon, Jin-Sil Choi
-
Patent number: 7998462Abstract: An improved linker which lacks chiral centers between a hydrophobic anchor for coupling to lipid-based particles and a targeting agent has suitable hydrophobic/hydrophilic properties for use in vivo.Type: GrantFiled: October 16, 2007Date of Patent: August 16, 2011Assignee: Kereos, Inc.Inventor: William D. McGhee
-
Publication number: 20110195030Abstract: Nanocapsule and nanoemulsion particle compositions having improved physical and pharmacological properties are provided. The nanocapsule or nanoemulsion particle composition can comprise a pharmaceutically acceptable liquid oil phase, a surfactant, and optionally a co-surfactant. The liquid oil phase can comprise a monoglyceride, a diglyceride, a triglyceride, a propylene glycol ester, or a propylene glycol diester. In certain embodiments, the nanocapsule or nanoemulsion particle composition can be lyophilized and subsequently re-hydrated without increasing the mean particle size and/or adversely affecting the potency or efficacy of a therapeutic agent (e.g., paclitaxel) present in the nanocapsules or nanoemulsion particles.Type: ApplicationFiled: October 14, 2009Publication date: August 11, 2011Applicants: The University of North Carolina at Chapel Hill, The University of KentuckyInventors: Russell J. Mumper, Xiaowei Dong
-
Publication number: 20110177009Abstract: Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a 19F MR contrast agent. Preferably, the carrier also acts as a contrast enhancement agent for MRI based on the principle of Chemical Exchange-dependent Saturation Transfer (CEST). To this end the shell encloses a cavity that comprises a paramagnetic chemical shift reagent, a pool of proton analytes, and the 19F contrast agent, and wherein the shell allows diffusion of the proton analytes.Type: ApplicationFiled: September 3, 2009Publication date: July 21, 2011Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Sander Langereis, Jochen Keupp, Holger Gruell, Dirk Burdinski, Danielle Beelen
-
Publication number: 20110165065Abstract: The present invention relates to a composition for the detection and the treatment of prostate cells and to methods for the diagnostic and therapeutic treatment of a human being using the composition according to the invention.Type: ApplicationFiled: February 8, 2011Publication date: July 7, 2011Applicant: Eberhard-Karls-Universitaet Tuebingen UniversitaetsklinikumInventor: Stefan Heckl
-
Patent number: 7966056Abstract: The present invention relates to a magnetic resonance imaging (MRI) method, in particular to a MRI method enabling early detection of myocardial ischemia and to compounds for use as MR contrast agents in the method.Type: GrantFiled: December 16, 2003Date of Patent: June 21, 2011Assignee: GE Healthcare ASInventors: Pal Rongved, Jan O. G. Karlsson, Karen Briley Saebo
-
Publication number: 20110117028Abstract: A device and methods for the non-invasive manipulation and detection of target objects such as cells, pathogens, microparticles, and nanoparticles in vivo using an external magnetic field are described. In one aspect, a device and method for capturing and detecting intrinsically magnetic target objects or target objects labeled with at least one magnetic particle within the area of interest using an in vivo flow cytometer are described.Type: ApplicationFiled: November 12, 2010Publication date: May 19, 2011Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSASInventor: Vladimir Pavlovich Zharov
-
Publication number: 20110117027Abstract: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.Type: ApplicationFiled: January 11, 2011Publication date: May 19, 2011Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
-
Patent number: 7927581Abstract: Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.Type: GrantFiled: April 4, 2005Date of Patent: April 19, 2011Assignee: Factor 1A, LLCInventors: Zhaoda Zhang, John C. Amedio, Peter D. Caravan, Stephane Dumas, Andrew Kolodziej, Thomas J. McMurry
-
Patent number: 7917188Abstract: A method for mapping a physico-chemical parameter using a chemical exchange saturation transfer contrast agent in Magnetic Resonance Imaging is used with agents having only one exchangeable entity pool, e.g. proton pool, by applying two different RF frequencies for pre-saturation of the contrast agent.Type: GrantFiled: April 21, 2006Date of Patent: March 29, 2011Assignee: Koninklijke Philips Electronics N.V.Inventors: Rene Theodorus Wegh, Jeroen Alphons Pikkemaat, Nicolaas Petrus Willard
-
Publication number: 20110064658Abstract: RGD-chlorophyll and RGD-bacteriochlorophyll conjugates that home and accumulate in necrotic tumor domains much longer than in tumor non-necrotic domains are provided for use in minimally invasive tumor-targeted imaging, tumor-targeted photodynamic therapy, and/or on-line prognosis of necrotic tumors.Type: ApplicationFiled: March 1, 2009Publication date: March 17, 2011Inventors: Avigdor Scherz, Liat Goldshaid, Yoram Salomon
-
Patent number: 7897140Abstract: Novel tetrapyrollic water soluble photosensitizing and imaging compounds and the methods of treating and imaging hyperproliferative tissue, e.g. tumors and hypervacularized tissue such as found in macular degeneration. Broadly, the compounds are tetrapyrollic photosensitizer compounds where the tetrapyrollic compound is a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide having 3 to 6 —CH2CONHphenylCH2CH(N(CH2COOH)2))(CH2N(CH2COOH)(CH2CH2N(CH2COOH)2)) groups or esters thereof or complexes thereof with gadolinium(III).Type: GrantFiled: June 30, 2006Date of Patent: March 1, 2011Assignee: Health Research, Inc.Inventors: Ravindra K. Pandey, Lalit Goswami, Joseph Spernyak, Peter Kanter, Richard Mazurchuk
-
Publication number: 20110044897Abstract: The invention relates to a method for targeting an imaging agent to cells of an animal to detect localized infections. More particularly, localized infections are detected by targeting imaging agents to inflammatory cells having receptors for a vitamin by using vitamin-imaging agent conjugates.Type: ApplicationFiled: May 23, 2008Publication date: February 24, 2011Inventors: Philip Stewart Low, Walter Anthony Henne, JR., Bindu Varghese, Ryan Rothenbuhler
-
Publication number: 20110038804Abstract: The invention relates to hyperpolarised 13C-?-ketoisocaproate, its use as imaging agent, an imaging medium comprising hyperpolarised 13C-?-ketoisocaproate and methods of 13C-MR detection wherein such an imaging medium is used. Further, the invention relates to methods of producing hyperpolarised 13C-?-ketoisocaproate.Type: ApplicationFiled: December 19, 2008Publication date: February 17, 2011Inventors: Anna Gisselsson, George Hansson, Sven Mansson, Rene In't Zandt, Magnus Karlsson, Pernille R. Jensen, Mathilde H. Lerche
-
Publication number: 20110033390Abstract: The invention relates to hyperpolarised 13C-alanine, its use as imaging agent, an imaging medium comprising hyperpolarised 13C-alanine and methods of 13C-MR detection wherein such an imaging medium is used. Further, the invention relates to methods of producing hyperpolarised 13C-alanine.Type: ApplicationFiled: February 3, 2009Publication date: February 10, 2011Inventors: Anna Gisselsson, Georg Hansson, Sven Mansson, Rene In't Zandt, Magnus Karlsson, Pernille R. Jensen, Mathilde H. Lerche
-
Publication number: 20100322867Abstract: A synthetic calcium phosphate-based biomedical material comprising gadolinium. The material may comprise a compound having the general chemical formula: Ca10?yGdy(PO4)6?x(SiO4)x(OH)2?z+y where 0<x<1.3 and 0<y<1.3.Type: ApplicationFiled: June 7, 2007Publication date: December 23, 2010Applicants: APATECH LIMITED, University Court of The University of AberdeenInventors: Iain Ronald Gibson, Janet Mabel Scott Skakle, Nigel Smith, Thomas Buckland
-
Publication number: 20100303731Abstract: Magnetic resonance systems, devices, methods, and compositions are provided. A nuclear magnetic resonance imaging composition includes, but is not limited to, a plurality of ferromagnetic microstructures configured to generate a time-invariant magnetic field within at least a portion of one or more internal surface-defined voids. In an embodiment, a plurality of ferromagnetic microstructures includes one or more selectively accessible ferromagnetic microstructures.Type: ApplicationFiled: May 29, 2009Publication date: December 2, 2010Inventors: Roderick A. Hyde, Jordin T. Kare, Wayne R. Kindsvogel
-
Publication number: 20100303733Abstract: Magnetic resonance systems, devices, methods, and compositions are provided. A nuclear magnetic resonance imaging composition includes, but is not limited to, a plurality of ferromagnetic microstructures configured to generate a time-invariant magnetic field within at least a portion of one or more internal surface-defined voids. In an embodiment, at least one of the plurality of ferromagnetic microstructures includes one or more targeting moieties attached thereof.Type: ApplicationFiled: May 29, 2009Publication date: December 2, 2010Inventors: Roderick A. Hyde, Jordin T. Kare, Wayne R. Kindsvogel
-
Publication number: 20100254912Abstract: Gadolinium+3 (Gd3+) containing (or incorporated) Prussian blue lattice contrast agents that can be used as an MRI contrast agent have unexpectedly improved r1 relaxivities of 1 or 2 magnitudes higher than the commercial Gd3+-chelates as well as exceedingly, non-toxic, low release of the Gd3+ ions into an aqueous environment at a pH of about 2 to about 7.5. The Prussian blue lattice containing Gd3+ ions therein can be used for clinical diagnosis intravenously to human beings for medical imaging. The particle sizes of the doped Prussian blue lattices are of a nanosize scale and are very stable against agglomeration.Type: ApplicationFiled: April 3, 2009Publication date: October 7, 2010Applicant: KENT STATE UNIVERSITYInventors: Songping D. Huang, Yongxiu Li, Mohammadreza Shokouhimehr
-
Patent number: 7807140Abstract: Polymeric chelating agents and metal chelates, particularly those of lanthanide metals and more specifically those of Gd(III), useful as contrast agents in magnetic resonance imaging (MRI) for therapeutic and diagnostic applications as well as clinical and biomedical research applications. The polymeric chelates are generated using ring-opening metathesis polymerization (ROMP). Polymers can have multiple sites for functionalization allowing for the synthesis of multimodal and targeted contrast agents. Hydroxypyridonate (HOPO)-based chelating moieties are integrated into a ROMP-derived polymer. More specifically, the HOPO-based chelating moiety is integrated into a benzonorbornadiene unit that constitutes the backbone of the polymer. The ROMP-derived polymer chelators can comprise multiple metal ions, particularly Gd(III) ions, in polymers of varying lengths to provide a series of agents with controlled relaxivites. Polymer chelates include those that are water-soluble.Type: GrantFiled: May 3, 2007Date of Patent: October 5, 2010Assignee: Wisconsin Alumni Research FoundationInventors: Laura L. Kiessling, Ronald T. Raines, Matthew J. Allen
-
Publication number: 20100233096Abstract: The invention relates to a dynamic nuclear polarisation method for producing hyperpolarised carboxylates or sulphonates or mixtures thereof wherein the carboxylate or sulphonate used in the method of the invention comprises certain inorganic cations. The invention further relates to compositions for use in that method.Type: ApplicationFiled: March 21, 2007Publication date: September 16, 2010Inventors: Mathilde H. Lerche, Magnus Karlsson
-
Publication number: 20100226852Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.Type: ApplicationFiled: December 21, 2009Publication date: September 9, 2010Applicant: NEW YORK UNIVERSITYInventors: Peter C. Brooks, Jennifer Roth, Abebe Akalu
-
Publication number: 20100226862Abstract: Microcapsule for injection into the bloodstream of a patient before a magnetic resonance acquisition pertaining to the bloodstream, include a magnetic resonance marking substance (in particular with at least one isotope associated with a specific resonant frequency) inside the microcapsule and an outer membrane that is impermeable to the marking substance. The microcapsule is overall biodegradable.Type: ApplicationFiled: March 4, 2010Publication date: September 9, 2010Inventor: Sebastian Schmidt
-
Publication number: 20100215587Abstract: A material useful as a MRI contrast agent used for medical imaging, drug delivery platform or other functions are provided as a class of non-gadolinium and non-iron oxide based materials that comprise Prussian blue materials or analogue materials. The materials may be used as T1-weighted and/or T2-weighted MRI contrast agents for imaging, including cellular imaging, in clinical diagnosis and biomedical research applications. The agent is a compound created from Prussian blue materials that is non-toxic, and can be internalized by cells through endocytosis. The Prussian blue materials may also be used for drug delivery applications. The Prussian blue materials may be administered orally to a subject in either medical imaging or drug delivery applications or dual modality MRI-Fluorescence imaging agent.Type: ApplicationFiled: February 23, 2010Publication date: August 26, 2010Applicant: KENT STATE UNIVERSITYInventors: Songping D. HUANG, Soumitra BASU, Anatoly K. KHITRIN, Mohammadreza Shokouhimehr, Eric Scott Soehnlen
-
Patent number: 7780953Abstract: The invention relates to a composition comprising acid magnetic particles (p) based on an iron compound, the acid magnetic particles (p) being complexed by one or more gem-bisphosphonate compounds, of formula I: X-L-CH(PO3H2)2??(I) in which: L represents an organic group connecting the X group to the gem-bisphosphonate group —CH(PO3H2)2; X represents a chemical group capable of reacting with a biovector; all or some of the X groups of the particles optionally being coupled to a biovector. The invention relates, also to a process for the preparation of the compositions and their use, in particular as contrast products for Magnetic Resonance Imaging (MRI).Type: GrantFiled: December 19, 2003Date of Patent: August 24, 2010Assignee: GuerbetInventors: Marc Port, Claire Corot, Isabelle Raynal, Olivier Rousseaux
-
Patent number: 7780947Abstract: New bifunctional chelation complexes are described. These are based on the structure of the so-called “TAME-HexA” molecule. The compounds are especially useful for forming chelation complexes with metal ions, including radioisotopes.Type: GrantFiled: December 3, 2004Date of Patent: August 24, 2010Assignees: Sloan-Kettering Institute for Cancer Research, Ludwig Institute for Cancer ResearchInventors: Enver Arslantas, Richard R. Schmidt, Peter M. Smith-Jones, Gerd Ritter
-
Publication number: 20100196283Abstract: The invention relates to a method of 13C-MR detection using an imaging medium comprising hyperpolarised 13C-lactate and to an imaging medium containing hyperpolarised 13C1-lactate for use in said method.Type: ApplicationFiled: July 25, 2008Publication date: August 5, 2010Inventors: Matilde H. Lerche, Anna Gisselsson, Georg Hansson, Sven Mansson, Rene in't Zandt, Magnus Karlsson, Pernille R. Jensen
-
Publication number: 20100166667Abstract: A method of determining the amount of intracellular manganese in the myocardium of an individual pre-administered with a manganese contrast agent, or a pharmaceutically acceptable salt thereof, comprising subjecting said individual to a MRI procedure to assess the signal intensity (SI) of images, or more preferably the longitudinal relaxation rate, R1 throughout said myocardium.Type: ApplicationFiled: January 18, 2008Publication date: July 1, 2010Inventors: Per Jynge, Arne Skjold, Henrik W. Larsson, Heidi Brurok